DOP2014000123A - Composiciones intranasales de dexmedetomidina y métodos de uso de ellas - Google Patents

Composiciones intranasales de dexmedetomidina y métodos de uso de ellas

Info

Publication number
DOP2014000123A
DOP2014000123A DO2014000123A DO2014000123A DOP2014000123A DO P2014000123 A DOP2014000123 A DO P2014000123A DO 2014000123 A DO2014000123 A DO 2014000123A DO 2014000123 A DO2014000123 A DO 2014000123A DO P2014000123 A DOP2014000123 A DO P2014000123A
Authority
DO
Dominican Republic
Prior art keywords
dexmedetomidine
methods
intranasal compositions
intranasal
compositions
Prior art date
Application number
DO2014000123A
Other languages
English (en)
Inventor
Geraldine A Henwood
John Joseph Kolenq Jr
Christopher T Sharr
Randall J Mack
Charles Alexander Freyer
Original Assignee
Recro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48613351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000123(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recro Pharma Inc filed Critical Recro Pharma Inc
Publication of DOP2014000123A publication Critical patent/DOP2014000123A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee formulaciones intranasales que comprenden dexmedetomidina, o una sal farmacéuticamente aceptable de ella, y sus usos.
DO2014000123A 2011-12-11 2014-06-09 Composiciones intranasales de dexmedetomidina y métodos de uso de ellas DOP2014000123A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161569255P 2011-12-11 2011-12-11

Publications (1)

Publication Number Publication Date
DOP2014000123A true DOP2014000123A (es) 2014-12-31

Family

ID=48613351

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000123A DOP2014000123A (es) 2011-12-11 2014-06-09 Composiciones intranasales de dexmedetomidina y métodos de uso de ellas

Country Status (21)

Country Link
US (2) US9795559B2 (es)
EP (2) EP2787970B1 (es)
JP (2) JP6268100B2 (es)
KR (1) KR102190009B1 (es)
CN (1) CN104470516A (es)
AU (2) AU2012352528B9 (es)
BR (1) BR112014019171A8 (es)
CA (1) CA2858721C (es)
CL (1) CL2014001515A1 (es)
CO (1) CO7000773A2 (es)
CR (1) CR20140318A (es)
DO (1) DOP2014000123A (es)
EC (1) ECSP14007644A (es)
HK (1) HK1203049A1 (es)
IL (1) IL232977B (es)
MX (1) MX367286B (es)
PE (1) PE20142314A1 (es)
PH (1) PH12014501273A1 (es)
RU (1) RU2692245C2 (es)
SG (2) SG11201403094TA (es)
WO (1) WO2013090278A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012000609A1 (en) 2010-06-16 2012-01-05 Cargill, Incorporated Starch-based compositions for latex replacement
EP2787970B1 (en) * 2011-12-11 2018-04-11 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US20160228433A1 (en) * 2013-09-24 2016-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal dhe for the treatment of headache
US20150098997A1 (en) 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
RU2648817C2 (ru) * 2013-10-07 2018-03-28 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для лечения абстинентных синдромов с использованием неседативных трансдермальных композиций на основе дексмедетомидина
WO2015054058A1 (en) 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Dexmedetomidine Transdermal Delivery Devices and Methods for Using the Same
ES2847936T3 (es) 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
MX2019007923A (es) 2016-12-31 2019-09-10 Bioxcel Therapeutics Inc Uso de dexmedetomidina sublingual para el tratamiento de la agitacion.
CN115154440A (zh) 2018-06-27 2022-10-11 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
CN109620802A (zh) * 2018-12-05 2019-04-16 杜皓 一种麻醉用鼻喷剂及其制备方法
CN111481506B (zh) * 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
CN112107544A (zh) * 2019-06-28 2020-12-22 四川普锐特药业有限公司 右美托咪定鼻喷剂、其制备方法及应用
CN116474218A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
MX2022000709A (es) 2019-07-19 2022-05-19 Bioxcel Therapeutics Inc Regimenes de tratamiento con dexmedetomidina no sedante.
CN113827590A (zh) * 2020-06-08 2021-12-24 四川普锐特药业有限公司 右美托咪定在助眠药物制备中的应用
AU2022205061A1 (en) * 2021-01-04 2023-07-06 Bioxcel Therapeutics, Inc. Dexmedetomidine treatment regimens
CN115137699B (zh) * 2021-03-29 2024-05-03 四川普锐特药业有限公司 一种增效防腐的右美托咪定鼻喷剂
CN113876776A (zh) * 2021-11-04 2022-01-04 江苏大学附属医院 一种复方鼻喷镇痛药剂及其制备方法
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
DE786264T1 (de) 1990-12-05 2000-11-02 The General Hospital Corp., Charlestown Vorrichtung zum Behandeln einen Lungengefässverengung und von Asthma
GB9111732D0 (en) 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5571840A (en) 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
US5713907A (en) 1995-07-20 1998-02-03 Endotex Interventional Systems, Inc. Apparatus and method for dilating a lumen and for inserting an intraluminal graft
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
PL330191A1 (en) 1996-05-29 1999-04-26 Orion Corp Soluble oxides for biological applications
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
DE19749724A1 (de) 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
AU1319200A (en) 1998-10-20 2000-05-08 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
AUPR184500A0 (en) 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
US6582457B2 (en) 2001-02-15 2003-06-24 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US20030022926A1 (en) 2001-05-07 2003-01-30 Lavand'homme Patricia Method for treating neuropathic pain and pharmaceutical preparation therefor
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US6864271B2 (en) 2002-11-12 2005-03-08 The Foundation For The Lsu Health Sciences Center Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
JP2006516262A (ja) 2002-12-17 2006-06-29 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Ｙ２受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050058696A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2006105205A1 (en) 2005-03-29 2006-10-05 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
EP1986642B1 (en) 2006-02-13 2013-11-13 Orient Pharma (Samoa) Co, Ltd Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
GB0611241D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
US20080021074A1 (en) 2006-06-29 2008-01-24 Questcor Pharmaceuticals, Inc. Pharmaceutical Compositions and Related Methods of Treatment
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
CN101057830A (zh) 2007-05-10 2007-10-24 北京天川军威医药技术开发有限公司 盐酸纳洛酮舌下喷雾给药系统或组合物及其制备方法
BRPI0821647A2 (pt) * 2007-12-21 2015-06-16 Schering Plough Healthcare Realce da fotosestabillização de oximetazolina
CN102639131A (zh) * 2009-05-15 2012-08-15 瑞克欧制药有限公司 舌下右美托咪定组合物及其使用方法
NZ597763A (en) * 2009-07-27 2014-07-25 Nocicepta Llc Methods for treatment of pain
WO2011085162A2 (en) * 2010-01-08 2011-07-14 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
EP2787970B1 (en) * 2011-12-11 2018-04-11 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof

Also Published As

Publication number Publication date
RU2692245C2 (ru) 2019-06-24
CL2014001515A1 (es) 2014-12-05
IL232977A0 (en) 2014-07-31
PE20142314A1 (es) 2015-01-23
BR112014019171A2 (es) 2017-06-20
EP2787970A4 (en) 2015-10-28
EP2787970A2 (en) 2014-10-15
MX367286B (es) 2019-08-13
JP2015513309A (ja) 2015-05-07
US20130178465A1 (en) 2013-07-11
HK1203049A1 (en) 2015-10-16
CA2858721A1 (en) 2013-06-20
AU2012352528A1 (en) 2014-07-10
JP6505177B2 (ja) 2019-04-24
US20180055764A1 (en) 2018-03-01
NZ626999A (en) 2016-07-29
JP2018030850A (ja) 2018-03-01
WO2013090278A2 (en) 2013-06-20
AU2012352528B2 (en) 2017-10-26
CR20140318A (es) 2014-10-28
BR112014019171A8 (pt) 2017-07-11
AU2018200591A1 (en) 2018-02-15
KR102190009B1 (ko) 2020-12-15
SG11201403094TA (en) 2014-10-30
WO2013090278A3 (en) 2014-12-24
CA2858721C (en) 2021-03-16
CO7000773A2 (es) 2014-07-21
RU2014128343A (ru) 2016-01-27
EP2787970B1 (en) 2018-04-11
AU2012352528B9 (en) 2017-11-02
KR20140107329A (ko) 2014-09-04
US10682311B2 (en) 2020-06-16
MX2014006961A (es) 2014-09-22
SG10201604653TA (en) 2016-07-28
IL232977B (en) 2019-01-31
EP3406247A1 (en) 2018-11-28
CN104470516A (zh) 2015-03-25
AU2018200591B2 (en) 2018-11-29
US9795559B2 (en) 2017-10-24
JP6268100B2 (ja) 2018-01-24
PH12014501273A1 (en) 2014-09-08
ECSP14007644A (es) 2015-11-30

Similar Documents

Publication Publication Date Title
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
IL244597B (en) Replication suppressors of influenza viruses, preparations containing them and their uses
CR20150462A (es) Inhibidores de erk y sus usos
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
CR20160419A (es) Nuevos compuestos biciclicos
CO7121325A2 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
DK2814504T3 (da) Protease inhibitor indeholdende sammensætninger, sammensætninger omfattende samme og metoder til fremstilling og brug af samme
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
MX2014004022A (es) Anticuerpos anti-htra1 y metodos de uso.
CO7020867A2 (es) Formulaciones de anticuerpo y metodos
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
AR093738A1 (es) Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia
IN2015DN04074A (es)
BR112015020053B8 (pt) Composições para cuidado oral
MX2013008559A (es) Derivados de leptina.
CR20140526A (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis
UY34514A (es) ?derivados miméticos de brasinoesteroides no esteroideos, composición, métodos y usos que los comprenden?.
TWD178969S (zh) 牙刷柄